%PDF-1.4
%
74 0 obj
<>
endobj
70 0 obj
[/CalGray<>]
endobj
71 0 obj
[/CalRGB<>]
endobj
131 0 obj
<>stream
Acrobat PDFWriter 4.05 for Power Macintosh
2003-06-02T10:38:21Z
2024-03-28T13:23:22-07:00
2024-03-28T13:23:22-07:00
QuarkXPress™ 4.11
application/pdf
Heather
uuid:b4a6e738-1dd1-11b2-0a00-5d0927bd3700
uuid:b4a6e73b-1dd1-11b2-0a00-5b0000000000
endstream
endobj
69 0 obj
<>
endobj
67 0 obj
<>
endobj
68 0 obj
<>
endobj
53 0 obj
<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/Type/Page>>
endobj
132 0 obj
[135 0 R]
endobj
133 0 obj
<>stream
1 g
419.25 750.75 137 10.25 re
f
0 g
53.25 54.25 504 1 re
f
BT
/TT0 8 Tf
0.2 Tw 423.553 36.75 Td
(The Journal of Rheumatology 2003; 30:7)Tj
0 Tw -370.102 -0.25 Td
(1654)Tj
ET
1 g
108.25 48.75 397 11.25 re
f
108.75 49.25 396 10.25 re
f
q
0 g
397 0 0 11.25 108.25 48.75 cm
/Im0 Do
Q
BT
0 g
/TT1 10 Tf
53.451 471 Td
(to fulfill the set of criteria. The performance of such a set of)Tj
-0.04 -12 Td
(criteria was observed in symptomatic OApatients for whom)Tj
2.16901 Tw -0.041 -12 Td
(the level of symptoms required at entry was quite high.)Tj
2.836 Tw 0.019 -12 Td
(Further studies are required to evaluate performance of)Tj
1.51199 Tw 0.029 -12 Td
(these criteria in other sets of patients, in particular, those)Tj
0.76601 Tw -0.075 -12 Td
(with lower symptomatic activity at entry, but who are also)Tj
0.25 Tw -0.081 -12 Td
(candidates for joint structure preserving OA)Tj
0 Tw 179.833 0 Td
(clinical trials.)Tj
/TT2 10 Tf
-179.826 -24 Td
(ACKNOWLEDGMENT)Tj
/TT1 8 Tf
1.07201 Tw 0.062 -10 Td
(The authors thank the following companies and their representatives for)Tj
1.008 Tw 0.023 -10 Td
(providing their database: Boehringer-Ingelheim France \(Laurence Salin\)\
;)Tj
1.453 Tw -0.066 -10 Td
(Fidia Farmaceutici SpA)Tj
1.403 Tw 82.335 0 Td
(\(Simonetta Piva\); Merck \(James A. Bolognese,)Tj
2.427 Tw -82.127 -10 Td
[(Elliot )32 (W)93.875 (. Ehrich, Ken E. )0.5 (T)62.625 (ruitt\); NEGMA-LERADS \(Alain )0.25 (T)]TJ
0 Tw 215.575 0 Td
(accoen,)Tj
1.74699 Tw -215.797 -10 Td
(Patrick Cohen\); Novartis \(Ornella Della Casa Alberighi, Alan Moore\);)Tj
0.14999 Tc 0 Tw 0.162 -10 Td
(Pharmacia )Tj
0 Tc 40.512 0 Td
[(\(Carl )-468.5 (Wallemark, )-530.125 (Jim )]TJ
0.146 Tc 83.282 0 Td
(Lefkowith\); )Tj
0 Tc 45.211 0 Td
[(and )-468.625 (Rotta )]TJ
0.15601 Tc 40.383 0 Td
(Research)Tj
0 Tc 0.2 Tw -209.434 -10 Td
(Laboratorium \(Lucio C. Rovati, Giampaolo Giacovelli\).)Tj
/TT2 10 Tf
0 Tw 0.008 -24 Td
(REFERENCES)Tj
/TT1 8 Tf
6.986 -10 Td
(1.)Tj
0.2 Tw 13 0 Td
(Altman RD, Hochberg MC. Degenerative joint disease. Clin Rheum)Tj
0 Tw 0.502 -10 Td
(Dis 1983;9:681-93.)Tj
-13.577 -10 Td
(2.)Tj
0.155 Tw 13 0 Td
(Bellamy N, Kirwan J, Altman R, et al. Recommendations for a core)Tj
0.2 Tw 0.505 -10 Td
(set of outcome measures for future phase III clinical trials in knee,)Tj
0.063 -10 Td
(hip and hand osteoarthritis. Results of consensus development at)Tj
0.867 Tw -0.048 -10 Td
(OMERACTIII. J Rheumatol 1997;24:799-802.)Tj
0 Tw -13.466 -10 Td
(3.)Tj
0.158 Tw 13 0 Td
(Altman R, Asch E, Bloch D, et al. Development of criteria for the)Tj
0.2 Tw 0.506 -10 Td
(classification and reporting of osteoarthritis. Classification of)Tj
0.164 Tw 0.122 -10 Td
(osteoarthritis of the knee. Diagnostic and Therapeutic Criteria)Tj
0 Tw -0.198 -10 Td
(Committee of the American Rheumatism Association. Arthritis)Tj
0.052 -10 Td
(Rheum 1986;29:1039-49.)Tj
-13.581 -10 Td
[(4.)-875 (Hochberg MC, Altman RD, Brandt KD, Moskowitz R)-49.75 (W)62.625 (, for the)]TJ
13.719 -10 Td
(T)Tj
0.2 Tw 4.137 0 Td
(ask Force: Design and conduct of clinical trials in osteoarthritis:)Tj
-4.141 -10 Td
(Preliminary recommendations from a task force of the)Tj
0 Tw -0.104 -10 Td
(Osteoarthritis Research Society. J Rheumatol 1997;24:792-4.)Tj
250.438 341.25 Td
[(5.)-875 (Carlsson AM. Assessment of chronic pain. I. Aspects of the )]TJ
0.2 Tw 13.524 -10 Td
(reliability and validity of the visual analogue scale. Pain)Tj
0 Tw 0.077 -10 Td
(1983;16:87-101. )Tj
-13.441 -10 Td
[(6.)-875 (Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt L)-34.625 (W.)]TJ
13.414 -10 Td
(V)Tj
0.16901 Tw 4.777 0 Td
(alidation study of WOMAC: a health status instrument for)Tj
0.2 Tw -4.763 -10 Td
(measuring clinically important patient relevant outcomes to)Tj
0.059 -10 Td
(antirheumatic drug therapy in patients with osteoarthritis of the hip)Tj
0 Tw -0.059 -10 Td
(or knee. J Rheumatol 1988;15:1833-40.)Tj
-13.606 -10 Td
(7.)Tj
0.10001 Tw 13 0 Td
(Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity)Tj
0.2 Tw 0.68 -10 Td
[(for osteoarthritis of the hip and knee. )64.25 (V)]TJ
0 Tw 126.337 0 Td
(alidation \321 value in)Tj
0.2 Tw -126.361 -10 Td
(comparison with other assessment tests. Scand J Rheumatol)Tj
0 Tw -0.073 -10 Td
(1987;Suppl 65:85-9.)Tj
-13.519 -10 Td
[(8.)-875 (Felson DT)68.75 (,)]TJ
0.16901 Tw 50.2 0 Td
(Anderson JJ, Boers M, et al: American College of)Tj
0 Tw -36.685 -10 Td
(Rheumatology. Preliminary definition of improvement in )Tj
-0.026 -10 Td
(rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.)Tj
-13.555 -10 Td
(9.)Tj
0.132 Tw 13 0 Td
(Dougados M, Leclaire P, van der Heijde D, Bloch DA, Bellamy N,)Tj
0.2 Tw 0.567 -10 Td
(Altman RD. Response criteria for clinical trials on osteoarthritis of)Tj
0.023 -10 Td
(the knee and hip: a report of the Osteoarthritis Research Society)Tj
0.07 -10 Td
[(International Standing Committee for Clinical )34.75 (T)]TJ
0 Tw 154.911 0 Td
(rials response)Tj
-155.034 -10 Td
(criteria initiative. Osteoarthritis Cart 2000;8:395-403.)Tj
-17.434 -10 Td
(10.)Tj
0.2 Tw 17 0 Td
(O\325Brien PC. Procedures for comparing samples with multiple)Tj
0 Tw 0.392 -10 Td
(endpoints. Biometrics 1984;40:1079-87.)Tj
-17.276 -10 Td
[(1)31.25 (1.)-875 (T)31.375 (illey BC, Pillemer SR, Heyse SP, Li S, Clegg DO, Alarcon GS.)]TJ
0.2 Tw 17.474 -10 Td
(Global statistical tests for comparing multiple outcomes in )Tj
0 Tw -0.103 -10 Td
[(rheumatoid arthritis trials. MIRA)-260.875 (T)31.375 (rial Group. Arthritis Rheum)]TJ
0.11 -10 Td
(1999;42:1879-88.)Tj
-17.641 -10 Td
[(12.)-875 (Bolognese JA, Ehrich EW, Schnitzer TJ. Precision of composite)]TJ
0.172 Tw 17.557 -10 Td
(measures of osteoarthritis efficacy in comparison to that of )Tj
0 Tw -0.067 -10 Td
(individual endpoints. J Rheumatol 2001;28:2700-4.)Tj
ET
q
30 31 552 730 re
W n
1 g
407.25 745.75 150 25 re
f
407.25 745.75 150 15.25 re
f
0 g
54.25 54.25 504 1 re
f
Q
q
122.25 523 353.25 196.75 re
W n
q
0 g
353.25 0 0 198.75 122.25 523 cm
/Im1 Do
Q
Q
BT
/TT0 8 Tf
125.252 511.25 Td
(Figure 4.)Tj
/TT1 8 Tf
32.223 0 Td
(OMERACT-OARSI set of responder criteria.)Tj
ET
q
0 0 612 792 re
W n
BT
0 0 0 rg
/T1_0 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
62 0 obj
<>/Filter/CCITTFaxDecode/Height 45/ImageMask true/Length 24/Name/I10/Subtype/Image/Type/XObject/Width 1588>>stream
ˁh?
endstream
endobj
64 0 obj
<>/Filter/CCITTFaxDecode/Height 830/ImageMask true/Length 7850/Name/I11/Subtype/Image/Type/XObject/Width 1472>>stream
&j$?Al
!3̮*Uʂs(s
9cr,rU98s0TYS8AWCr$9csa炬r!G!9 rEqc,rd99\rr,r)@䜂aX+͆H)ȏ̎̾]DtGGDv&V}:1F#t^=q]:#y]ͣqd|?}EyyDvm2<]|#9ȏp_#Ota>G./D|#\R쎋ClG>GDq/ٌ| hZH\4a
&C$m&C WX[M2JLA~4aoNzM4aAj?HmXI&K4l0T0[|0܈'f w?{"
K!K%]CD`CC_!`CE^A˲jB <oP@P 2t'4
0'Bi&aT
)0a8@L0iQij¦A,(T-h5C -Pa8uꅡaQɴ8UTGISatLךfO&ޒ'yBӚnrԝPMӃ8I抎3.O
&43NV&`zNt
?{A:M9 Dw?]w]ivWֵ6k#ߧXuWzz'wT'G?[8l1Z__(___~k}.+?W#ASiUuȎ_/ҿ_kk-lkz^Ky~ޞ뽇@|*if~Vj{]?{/i4tJ)/C0i
0lSNT 0jqvqQwIUڪiMM6A
4i4M4f.&a6WKM0OMWgK{
M0TDE x|<kCB"ˆ!Aaa0!"DE?"#6`̣K`@?%LD$ T5 <<L*`TBU8p39VG'&^
z
t[4 ~k!!1%!r
d?aSPCa
" &
a0M[UPah1M4ySs}=Mh<O''GӠpg.fNpaOO\&6SMM]{k_[K|7I
E-$3z~\?W/կ+^_wop4/ޏo!}]A$}{dGV$JҭLׯZG${ma$^FvAmo*=訥Ka<JL56#!pҺm.!|GJWńFƃjt4UasD]_LtGH3&{AmBa4 j=H m'aab"#"vү!a?A@q}_k}u_}O__ww}}8˳Bh49C炜c9'0AD9P\Ô9!hr 䜧!PP2 :4/2AXr0eYZ9\U
^VeAC(l(r+BYJT(Hh*e qeWgAF9܅rC9*A9NTPP+
*Y=<'o#} Ƕmmu]u=vy,G\|@5'hFw2If0]]RW O_pAm?KoG-֟_zMxa^oo#kX"@K.X@;5[ioD oNH?wA4/}\~Tohxڧkx0oL@]*s06JamX mE0ZMq Z2 ib[iqXkkk h1
ze鿯!c9C(arcr+s9$90&9c9999-P 6Lr19Ng8P#qCnh)υYCg*(sC(J
Ԭ)9I
NUETw'frhq pק#dp0GH)5IˆpBs.E#xtGDx/S]2Ge##hG9G2tGe<\Dp#(ˌdvGGDxDs#q莈菗eцo#:.9E̎ᜎ3 G|9dۿ k_aK4_m/_
~?d܆@{!0"@L h05G@ƤUԂ
^Z8Tz
:wNndp@j#M,8pVG
WU֞_"A`D
!A.D|*Uτ/BCjl!Ba4! a!4a08AH
Pi". u0jBh4-Ba5A*M64a?u[Nj=ʅ9GTsmq4MiPzF}nh&ڤsLvh3Ś})=83 jt ޝ
8hwmk
46|8i}'OnoPJyJA5:[o֗~_#Oi87ү^ޚ_ ~ kV=.wU{?<`
Uv{]{!^C̉f)ȟDȐG}+,uQ_PPiOL7Eo6hZK{K}ZZޯmZ4
.G
ۣm-xkG}Wak3iyvԂZh_W}KaT㰄_j[uJUK|2w+{ӵ
S '`4jii5a+;j)6I0:j{ iƛNh: iڤU+&o M^A<7N_=?jNn@^zuc"0&B"aM04i!ZhD3``3EkaP"4D׳8mȏ~ݭ+ovMku4/j{%(vPҎI4:kt6aBOTa2<0=qF_`?O_K C!^@ڂ$:D3@@LCPh*8
?MSZUO<
P^>@p?ô{mCC4psLaMWeՃ:M1a>aӨ[C.'E`oHg]U٬9H{ c 2
/~4
ZL 0P@z
0a0aдhX`4,'qjPiƚQZMRL0Jq5Tq;G=ta[ۓ_bI&OA CrpAG@_E94
0a~ˡ!~!El%l"Ys0PT!i&$0PhZaSl0M
SM_jiwm h 3-7aR9tzѷGpNNr瓭-沈#ھdG-I_Jm'I&ޗUaos#uzXHV_j4Faa
+ ⭪aJu[-ʆ8lP0K0Ɯ0iLqiiCVT㍦M;cuNڤiBIva8m@_L&<
[?h0'k
jB! Ej `!B([B? m
[qH0Tbix?k
?<Hn9@09 ,d- <& x7A
C$<8E
)rhUPMUUBiWi/TԁC 94spf84@ՍMSô^]R
4p>^ǫ _h0_G5Kl0sa<lV-4vBvk! Gx0[;8ùpk%w.}!<tљ K!y܂`aE
!h8aBha
B
0ha(ACa0Aa0@a5PSTj&Za
S a8a#YNsn\QΎ=G:7Q7P?$Mw7zn'9Μ3Näܟ`$H?OONA晢44zpgܟAa M>L&oa>/k'NMե~
=W߽v_i$]_ָ/WoCIxҵ@`un, Du/zX|?__Tg]h _WVUS^Zntpp@m_mhmIRk=7/!;^8o$KMoGuIzL;$)R7K8{#dGA}nwKmJ_uҠ4p2`$OJúOkk͆W~g3HV+ʎ>3jT{}"z!4ԧu&V\ZU}k{}[Wk qtp6)x[v_6iUCI5A駫IEEpmޭ^j}ئ)ٚ\SQM&m'mS ZnڨQLRuL MIݠALkj=ꩅP@4g?0fM4>5G x 䑰
`&aK#@H!E#0B ˁ!!A0@L!l-#DDRrRAl5